Title : Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216.

Pub. Date : 2022 Jan

PMID : 34667112






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Pancreatic cancer cell dependencies on different BCL-2 family proteins and the efficacy of the combination of GEM and DT2216 (a BCL-XL proteolysis targeting chimera or PROTAC) were determined by MTS, Annexin-V/PI, colony formation, and 3D tumor spheroid assays. DT2216 annexin A5 Homo sapiens